Cgm Dexcom denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your Dexcom CGM as Duplicate Therapy

Aetna's duplicate-therapy denial means the plan believes you are already receiving a device or benefit that serves the same monitoring function as a Dexcom continuous glucose monitor. In practice this most often arises when a traditional blood glucose meter (BGM) is active on your account, or when a different CGM was recently dispensed. The plan argues that two glucose-monitoring tools covering the same clinical purpose are not both medically necessary.

This denial is routinely overturned on appeal because a Dexcom CGM and a fingerstick meter are not clinically equivalent. A CGM provides real-time trend data, directional arrows, and low/high alerts that a fingerstick cannot replicate. Your prescriber can document specifically why the CGM offers distinct clinical value for your individual management needs — for example, hypoglycemia unawareness, nocturnal lows, or dose-adjustment decision-making — that a BGM does not address.

## Your Federal Appeal Rights

• Internal appeal: Submit within the timeframe shown on your denial letter (typically 180 days). Aetna must decide within 30 days for non-urgent requests or 72 hours for expedited/urgent requests.
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, you have the right to an independent external review. For most plans this window is roughly four months from the final internal denial. An independent review organization (IRO) — not Aetna — makes the binding decision.
• Expedited review: If your condition is urgent, request expedited external review simultaneously with the internal appeal.

## Documentation to Gather

1. Distinct clinical need letter: A letter from your endocrinologist or prescriber explaining why CGM provides monitoring capabilities that your current BGM cannot replicate for your specific case. 2. Diagnosis and history records: Chart notes confirming your diabetes diagnosis, duration, and current insulin or medication regimen. 3. Hypoglycemia or variability documentation: Any records of hypoglycemic episodes, A1c trend data, or glucose variability that supports the need for continuous rather than intermittent monitoring. 4. Prior device records: Documentation of what device is active and why it is functionally different from the Dexcom. 5. Applicable guideline reference: Your prescriber should cite the relevant guideline organization (e.g., the American Diabetes Association Standards of Care) that addresses CGM use in patients with your profile — without fabricating specific numbers, your chart should map to the published criteria.

## Criteria-Mapping Structure

Pull Aetna's published medical policy for CGM (available on Aetna's website or by request). List each coverage criterion exactly as written. Next to each criterion, document the specific chart fact that satisfies it — diagnosis code, medication list, visit note date, and prescriber statement. This side-by-side mapping is the most persuasive format for a medical reviewer.

A well-documented appeal demonstrating that a CGM and a BGM are not therapeutic duplicates succeeds frequently. Act promptly — deadlines are strict.